Table 2.

Univariate and multivariate regression analysis of risk factors for developing AKI

VariableUnivariate analysis OR (CI)Multivariate regression analysisP value
Age1.007 (0.987–1.027)0.981 (0.952–1.011)0.2
Baseline CrCl (MDRD)0.989 (0.980–0.997)*
Baseline CrCl (CKD-epi)0.978 (0.964–0.993)*0.972 (0.951–0.993)*0.0082
APACHE II1.045 (0.991–1.102)
Malignancy2.690 (1.265–5.717)*2.745 (1.189–6.339)*0.018
Prior episode of AKI8.183 (2.528–26.487)*6.311 (1.621–24.565)*0.0079
Current VAN exposure > 7 days1.881 (0.951–3.724)1.722 (0.785–3.777)0.18
Concurrent ICU stay2.313 (1.170–4.574)*2.497 (1.158–5.385)*0.02
Vasopressor exposure**2.462 (1.119–5.417)*
No. of days vasopressor given concurrently**1.273 (0.992–1.634)
No. of nephrotoxic agents given concurrently2.550 (1.073–6.062)*
Duration of VAN therapy (days)1.051 (0.967–1.142)
Average trough ≥ 15 μg/ml1.495 (0.752–2.972)1.128 (0.510–2.492)0.77
  • OR, odds ratio; CI, 95% confidence interval.

  • *, P value < 0.05; **, n = 37, too small to include this variable in the multivariate model.